Global healthcare group Fresenius has officially launched its corporate venture capital fund, Fresenius Ventures, signaling a major commitment to fostering innovation. The new unit is backed by an intended investment volume of over €200 million over the next five years. This strategic initiative is designed to connect the company with pioneering founders, breakthrough technologies, and novel business models across the healthcare landscape.
A Strategic Vision for Innovation
The creation of Fresenius Ventures is a core component of the company's overarching #FutureFresenius strategy. According to CEO Michael Sen, the fund acts as a strategic instrument to gain early access to promising healthcare innovators and entrepreneurial talent. This approach aims to strengthen Fresenius' innovation capabilities within the ecosystem and tap into adjacent fields for future growth.
Investment Focus and Scope
With its substantial capital commitment, the fund will target growth areas that are adjacent to Fresenius' existing strategic platforms in BioPharma, MedTech, and Care Provision. Potential investment areas include cutting-edge fields such as precision nutrition, microbiome research, and new therapeutic modalities. Digital care provision solutions also represent a key area of interest for the new venture capital arm.
Fresenius Ventures will support companies from early financing rounds through to their growth stage, offering a flexible investment mandate. This allows the fund to build a diverse portfolio of healthcare innovators poised for significant impact. All investments will be conducted in line with Fresenius' established capital allocation approach, ensuring strategic alignment and financial discipline.
Experienced Leadership at the Helm
To spearhead this initiative, Fresenius has appointed Dr. Thomas Michael Thestrup as the Managing Director and Head of Fresenius Ventures. Dr. Thestrup joins from Angelini Ventures, an international healthcare venture capital company, bringing extensive industry and investment expertise. His leadership is expected to be instrumental in identifying and nurturing high-potential startups within the sector.
Dr. Thestrup's career spans over 15 years in research, health technology, and the pharmaceutical industry, with prior roles at Lundbeck A/S and UCB. His background also includes experience in life science ventures at Sunstone Capital and a Ph.D. from the Max Planck Institute of Neurobiology. This diverse experience provides him with a comprehensive understanding of the healthcare innovation lifecycle.
A Founder-Centric Approach
Fresenius Ventures is positioned to offer more than just capital to its portfolio companies. The new unit will provide founders with access to Fresenius' deep medical, regulatory, and operational expertise across global markets. This comprehensive support system is designed to help innovators accelerate their progress from development to commercialization.
Dr. Thestrup emphasized that the fund will back innovators with the experience and conviction that founders expect from a strategic partner. Portfolio companies will gain unique access to the clinical, scientific, and academic ecosystems where significant progress in healthcare occurs. This network provides a distinct advantage for emerging companies seeking to make a meaningful impact.
The launch of Fresenius Ventures marks a pivotal move for the healthcare giant, underscoring its commitment to driving external innovation. By dedicating substantial capital and expert resources, Fresenius is positioning itself to influence and benefit from the next generation of healthcare advancements. This strategic vehicle is poised to strengthen the company's long-term growth while supporting transformative solutions in medicine.